Globeflex Capital L P Sells 4,321 Shares of ICON Public Limited (NASDAQ:ICLR)

Globeflex Capital L P lowered its position in ICON Public Limited (NASDAQ:ICLR) by 8.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 48,363 shares of the medical research company’s stock after selling 4,321 shares during the quarter. ICON Public comprises approximately 0.9% of Globeflex Capital L P’s portfolio, making the stock its 25th largest holding. Globeflex Capital L P owned approximately 0.06% of ICON Public worth $10,142,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sierra Ocean LLC bought a new position in shares of ICON Public during the fourth quarter valued at about $29,000. Park Place Capital Corp increased its stake in shares of ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 166 shares in the last quarter. Private Trust Co. NA increased its stake in shares of ICON Public by 48.8% during the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 82 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after buying an additional 169 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its holdings in shares of ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares during the last quarter. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Stock Up 3.1 %

Shares of ICLR stock opened at $184.58 on Friday. The company has a market capitalization of $14.91 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 1.86 and a beta of 1.21. ICON Public Limited has a one year low of $174.93 and a one year high of $347.72. The company’s fifty day moving average price is $196.16 and its 200-day moving average price is $231.67. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. The company had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. Sell-side analysts expect that ICON Public Limited will post 13.38 EPS for the current fiscal year.

Analysts Set New Price Targets

ICLR has been the topic of a number of recent analyst reports. Barclays cut their price target on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating on the stock in a report on Friday, February 21st. Leerink Partners restated an “outperform” rating and issued a $255.00 target price (down previously from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Citigroup dropped their target price on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Truist Financial dropped their target price on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Finally, Robert W. Baird dropped their target price on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $279.17.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.